drugset / Trial / NCT03806790

Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris

NCT03806790 ↗

Phase 3 Completed 182 enrolled LEO Pharma
RandomizedParallel-groupOpen-labelTreatment

Summary

Comparison of the efficacy of LEO 90100 foam with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.

Timeline

Start
2019-01-24
Primary completion
2019-06-10
Completion
2019-06-10

Outcome

Missed primary endpoint

registry analysis (superiority test); LEO 90100 Foam vs Dovobet® Ointment; p = 0.120; Odds Ratio (OR) 5.80 (95% CI 0.68 to 49.16); Fisher Exact NCT03806790 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcipotriene Other / unclassified — Topical
Comparator betamethasone dipropionate Small molecule — Topical

Indications